Abstract

We have developed a novel miniature robotic device (HeartLander) that can navigate on the surface of the beating heart through a subxiphoid approach. This study investigates the ability of HeartLander to perform in vivo semiautonomous epicardial injections on the beating heart. The inchworm-like locomotion of HeartLander is generated using vacuum pressure for prehension of the epicardium and drive wires for actuation. The control system enables semiautonomous target acquisition by combining the joystick input with real-time 3-dimensional localization of the robot provided by an electromagnetic tracking system. In 12 porcine preparations, the device was inserted into the intrapericardial space through a subxiphoid approach. Ventricular epicardial injections of dye were performed with a custom injection system through HeartLander's working channel. HeartLander successfully navigated to designated targets located around the circumference of the ventricles (mean path length=51+/-25 mm; mean speed=38+/-26 mm/min). Injections were successfully accomplished following the precise acquisition of target patterns on the left ventricle (mean injection depth=3.0+/-0.5 mm). Semiautonomous target acquisition was achieved within 1.0+/-0.9 mm relative to the reference frame of the tracking system. No fatal arrhythmia or bleeding was noted. There were no histological injuries to the heart due to the robot prehension, locomotion, or injection. In this proof-of-concept study, HeartLander demonstrated semiautonomous, precise, and safe target acquisition and epicardial injection on a beating porcine heart through a subxiphoid approach. This technique may facilitate minimally invasive cardiac cell transplantation or polymer therapy in patients with heart failure.

Highlights

  • We have developed a novel miniature robotic device (HeartLander) that can navigate on the surface of the beating heart through a subxiphoid approach

  • M yocardial injection therapy, which is based on the rationale of improving cardiac function in situ by introducing tissue-engineered materials into an infarct area, is emerging as a therapeutic strategy for postmyocardial infarct heart failure.[1,2,3,4]

  • This therapy is currently dominated by transcatheter endocardial approaches, direct epicardial injection offers some advantages such as easy detection of target myocardial infarct lesions, decreased likelihood of cerebrovascular complications,[5] and superior site specific efficacy.[6]

Read more

Summary

Methods

The HeartLander system consists of a surgical user interface and patient-side instrumentation. The patient-side instrumentation translates the commands of the surgeon into the appropriate robotic actions through the support system, which consists of the external motors, vacuum pumps, and computer control system. This instrumentation drives a miniature tethered crawling device located within the intrapericardial space of the patient. This tethered design allows the crawler, the therapeutic portion of the robotic system, to be miniature, lightweight, passive, and disposable

Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.